光敏剂
氯
光动力疗法
癌症研究
化学
消炎药
医学
光化学
药理学
有机化学
作者
Hai-Rong Yu,Ziling Huang,Jiale Wu,Ziming Zhao,Yabing Hua,Yihua Yang
出处
期刊:Nanomedicine
日期:2025-01-29
卷期号:: 1-12
标识
DOI:10.1080/17435889.2025.2456450
摘要
Photodynamic therapy (PDT) involves the activation of photosensitizers (PSs) by visible laser light at the target site to catalyze the production of reactive oxygen species, resulting in tumor cell death and blood vessel closure. The efficacy of PDT depends on the PSs, the amount of oxygen, and the intensity of the excitation laser. PSs have been extensively researched, and great efforts have been made to develop an ideal photosensitizer. Chlorin-e6 is an FDA-approved second-generation PSs that has attracted widespread research interest in the medical field, especially with respect to antitumor and anti-inflammatory activity. Chlorin-e6 possesses the advantages of a large absorption coefficient, high strength, low residue in the body, and relatively high safety and thus has promising application prospects. Here we review the use of chlorin-e6 in PDT and discuss the prospects of further development of this technology.
科研通智能强力驱动
Strongly Powered by AbleSci AI